EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Josef S SmolenRobert B M LandeweSytske Anne BergstraAndreas KerschbaumerAlexandre SeprianoDaniel AletahaRoberto CaporaliChristopher John EdwardsKimmie L HyrichJanet E PopeSavia de SouzaTanja Alexandra StammTsutomu TakeuchiPatrick VerschuerenKevin L WinthropAlejandro BalsaJoan M BathonMaya H BuchGerd-Rüdiger R BurmesterFrank ButtgereitMario Humberto CardielKaterina ChatzidionysiouCatalin CodreanuMaurizio CutoloAlfons A den BroederKhadija El AoufyAxel FinckhJoão Eurico FonsecaJacques-Eric GottenbergEspen A HaavardsholmAnnaMaria IagnoccoKim LauperZhanguo LiIain B McInnesEduardo F MyslerPeter NashGyula PoorGorica G RisticFelice RivelleseAndrea Rubbert-RothHendrik Schulze-KoopsNikolay StoilovAnja StrangfeldAnnette van der Helm-van MilElsa van DuurenThea P M Vliet VlielandRené WesthovensDésirée Mfm van der HeijdePublished in: Annals of the rheumatic diseases (2022)
These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.